The anticoagulants apixaban, dabigatran and rivaroxaban are more cost-effective than warfarin in the prevention of strokes among patients with nonvalvular atrial fibrillation, according to a study in Stroke: Journal of the American Heart Association. The costs analyzed in the review were associated with clinical events, visits with doctors, medicines, testing and adverse events.
Study: Some anticoagulants more cost-effective than warfarin
SmartBrief Job Listings for Health Care
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||
|Compliance and Ethics Director||
Sysmex America, Inc.